Covaxin

  • Covaxin demonstrates interim clinical efficacy of 81%
    Hyderabad, March 3 (IANS) Bharat Biotech on Wednesday announced the first interim analysis of Covaxin, which shows the efficacy of the Covid-19 vaccine to be at 81 per cent. The Hyderabad-based vaccine maker said whole virion inactivated Covid-19 vaccine candidate demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research
  • AIIMS: Covaxin effective for 9-12 months, no serious side-effects so far
    New Delhi, February 13 (IANS): Mathematical calculations indicate that Covaxin may provide immunity against Covid-19 for 9 to 12 months, and there may be a booster shot after this period elapses, Y.K. Gupta, the President of AIIMS Bhopal and Jammu, told IANS. Stressing on the safety and effectiveness of Covaxin, Gupta, former Dean (Academics), and ex-Head, Department of Pharmacology, AIIMS, New Delhi, said that no death has been reported so far due to Covaxin, nor has there been any
  • India says local COVID-19 vaccine final trials could end within two months
    NEW DELHI, November 23 (Reuters): India's health minister said on Sunday a locally-developed COVID-19 vaccine candidate could complete its final trials in a month or two, raising hopes for a rapid roll-out in a country with the world's second highest number of infections. The state-run Indian Council of Medical Research (ICMR) and privately-held Bharat Biotech this month started third-stage trials of COVAXIN, in a process that would involve 26,000 volunteers. It is
  • Clinical trials begin for Bharat Biotech's Covid-19 vaccine
    Hyderabad, July 17 (IANS): Hyderabad-based Bharat Biotech on Friday announced that the Phase-I clinical trials of India's first indigenous Covid-19 vaccine Covaxin began across the country on July 15.   "This is a randomised, double-blind, placebo-controlled clinical trial on 375 volunteers in India," the company said in a brief statement.   The leading vaccine maker had announced on June 29 that it successfully developed Covaxin in collaboration wit